| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 79.43 | 4.9% | 9.0% |
| Total Income | 79.43 | 4.9% | 9.0% |
| Expenditure | 85.56 | 0.9% | 1.9% |
| PBT | -6.36 | 41.3% | 41.4% |
| Net Profit | -6.35 | 41.7% | 40.9% |
| OPM | -7.71% | 6.36pp | 7.52pp |
| NPM | -7.99% | 6.41pp | 6.75pp |
| EPS | -0.15 | 42.3% | 42.3% |
AngioDynamics Reports Q2 FY2026 Results; Med Tech Growth Drives Profitability
04 May 2026 · 4 May, 1:51 am
Summary
AngioDynamics reported net sales of $79.4 million for the second quarter of fiscal year 2026, representing an 8.8% increase compared to the prior-year quarter. Med Tech net sales grew by 13.0%, reaching $35.7 million. The company's GAAP gross margin improved to 56.4%, a 170 basis point increase year-over-year. Adjusted EBITDA for the quarter was $5.9 million, compared to $3.1 million in the same period last year. The company raised its full year FY 2026 guidance for net sales and Adjusted EBITDA.
Key Highlights
- 1
Net sales for the second quarter of fiscal year 2026 were $79.4 million, an increase of 8.8% compared to the prior-year quarter.
- 2
Med Tech net sales increased by 13.0% to $35.7 million compared to $31.6 million in the prior-year period.
- 3
Auryon sales were $16.3 million, reflecting an increase of 18.6%.
- 4
The Mechanical Thrombectomy business delivered sales of $11.0 million, up by 3.9%.
- 5
NanoKnife sales increased by 22.2% to $7.3 million, including 14.4% growth in probes.
- 6
GAAP gross margin was 56.4%, which is 170 basis points higher compared to the second quarter of fiscal 2025.
- 7
Adjusted EBITDA in the second quarter of fiscal 2026 was $5.9 million, compared to $3.1 million in the second quarter of fiscal 2025.
Management Comments
Jim Clemmer
"We delivered an excellent second quarter, with continued strong Med Tech growth driving our overall performance," commented Jim Clemmer, President and Chief Executive Officer of AngioDynamics, Inc. "Across our Med Tech portfolio, we're seeing the benefits of our strategic transformation as our innovative platform technologies, from Auryon to Mechanical Thrombectomy to NanoKnife, continue taking share in large, attractive markets. The momentum across our technology platforms demonstrates the strength of our diversified Med Tech portfolio. We will continue to invest in the long-term growth of our Med Tech portfolio. During the quarter, we advanced several important initiatives, including securing FDA approval on the IDE for right-sided endocarditis and the AlphaVac line extension. In addition, we received FDA IDE approval for our AlphaVac blood return study, an important milestone as we expand our portfolio of best-in-class solutions for physicians treating acute pulmonary embolism.” Mr. Clemmer continued, “Importantly, our strong top-line growth, combined with disciplined execution of our operating initiatives, translated into another quarter of positive adjusted EBITDA and cash generation. With our differentiated technology portfolio, proven commercial execution, and strong balance sheet, we remain confident in delivering sustained, profitable growth throughout the year.”
Howard Donnelly
“Jim has spearheaded our multi-year strategic transformation that reshaped our product portfolio, captured significant opportunities in the large, global MedTech market, and delivered a substantially enhanced top-line growth profile for shareholders,” said Howard Donnelly, AngioDynamics Chairman of the Board. “Jim’s dedication to mentoring our people and cultivating a standard of excellence ensures we have a strong foundation to pursue growth opportunities across the MedTech market through clinical development, and new products and indications that will enable us to help treat substantially more patients. We are grateful for Jim’s contributions and his commitment to a seamless transition and look forward to working together to identify our next leader who will drive continued success for our employees, customers, and shareholders.”
Informational and educational content only. Not investment advice.